A Phase 3 interventional study of Leucovorin Calcium and Fluorouracil in Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma and Resectable Pancreatic Adenocarcinoma, sponsored by Erasmus Medical Center. Active, not recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing leucovorin in Pancreatic Neoplasms — 8 open to participants now, 12 under way, 4 of them phase 3. Leucovorin · Pancreatic Neoplasms.
Among the 37 studies testing leucovorin in Pancreatic Neoplasms, this one is the 4th largest by planned enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →8 of the 37 studies testing leucovorin in Pancreatic Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Hopital Foch · Sites in France
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
National Health Research Institutes, Taiwan · Sites in Taiwan
Ages 20+
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
Leucovorin: first FDA approval 1952 (LEUCOVORIN CALCIUM). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 23 · Phase 3 8
First in 1997; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 378 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 80 across the 37 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 37 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 2 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing leucovorin in Pancreatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04927780Phase 3Erasmus Medical CenterPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | 2027-01 |
| NCT06217042Phase 3Fudan UniversityHR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer | 2027-03-30 |
| NCT03977233UNC Lineberger Comprehensive Cancer CenterTumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies testing leucovorin in Pancreatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2).
The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the intervention arm (arm 1) start with neoadjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours). Cycles are repeated every 14 days. After eight cycles, surgical resection is performed in the absence of unresectable or metastatic disease. After resection, four cycles of adjuvant mFOLFIRINOX are scheduled.
Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Oxaliplatin · Procedure: Resection
Patients in the comparator arm (arm 2) start with surgery. After resection, 12 cycles of adjuvant mFOLFIRINOX (consisting of oxaliplatin 85 mg/m², irinotecan 150 mg/m², leucovorin 400 mg/m², all at day 1, and fluorouracil continuous IV infusion 2.4 g/m² over 46 hours) are scheduled.
Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Oxaliplatin · Procedure: Resection
IV
IV
IV
IV
Open or minimally-invasive pancreatectomy.
Overall survival
The time between randomization and death from any cause. Patients alive at last follow-up are censored.
Time frame: Up to 5 years after randomization.
Progression free survival
The time between randomization and locoregional progressive disease before or during treatment (resulting in irresectability), the occurrence of distant metastases, recurrent pancreatic cancer after surgery or death from any cause. Patients alive and free of these events at last follow-up are censored.
Time frame: Up to 5 years after randomization.
Distant metastases free survival
The time between randomization and the occurrence of distant metastases or death from any cause. Patients alive and free of these events at last follow-up are censored.
Time frame: Up to 5 years after randomization.
Locoregional progression free survival
The time between randomization and locoregional progression before or during treatment (resulting in irresectability), locoregional recurrence after resection or death from any cause. Patients alive and free of these events at last follow-up are censored.
Time frame: Up to 5 years after randomization.
Distant metastases free interval
The time between randomization and the occurrence of distant metastases. Distant metastases are considered an event and patients are censored at death or last follow-up when without this event.
Time frame: Up to 5 years after randomization.
Locoregional progression free interval
The time between randomization and locoregional progression before or during treatment (resulting in irresectability), or locoregional recurrence after resection. Locoregional progressive disease before or during treatment or locoregional recurrence after resection are considered an event and patients are censored at death or last follow-up when free of these events.
Time frame: Up to 5 years after randomization.
Chemotherapy start rate
The percentage of patients who received at least one cycle of scheduled chemotherapy.
Time frame: 4 months
Number of chemotherapy cycles received.
The number of mFOLFIRINOX cycles patients received.
Time frame: 9 months
Chemotherapy completion rate
The percentage of patients who completed all cycles of scheduled chemotherapy.
Time frame: 9 months
Dose intensity
The amount of drug delivered as a percentage of planned dose according to the protocol.
Time frame: 9 months
Staging laparoscopy rate
The percentage of patients that actually underwent a staging laparoscopy, regardless whether a surgical exploration or resection was performed.
Time frame: At the time of surgery.
Laparoscopy yield
The percentage of patients that underwent staging laparoscopy and were diagnosed with metastatic or unresectable disease during this procedure.
Time frame: At the time of surgery.
Surgical exploration rate
The percentage of patients who underwent a surgical exploration (open or minimally-invasive), regardless whether a resection was performed.
Time frame: At the time of surgery.
Resection rate
The percentage of patients that underwent a curative-intent resection.
Time frame: At the time of surgery.
Microscopically margin-negative (R0) resection rate
The percentage of patients that underwent a microscopically margin-negative (R0) resection. The resection is considered R0 if there is no tumor within 1 mm of the margins.
Time frame: At the time of surgery.
Lymph node-negative (N0) resection rate
The percentage of patients that underwent a resection with negative lymph nodes (N0) in the surgical specimen.
Time frame: At the time of surgery.
Pathologic response
Tumor regression score in the surgical specimen
Time frame: At the time of surgery.
Adverse events as assessed by the CTCAE version 5.0
Adverse events are assessed during neoadjuvant therapy and adjuvant therapy.
Time frame: Until 30 days after last chemotherapy.
Postoperative complications
According to the Clavien-Dindo classification and by the International Study Group of Pancreatic Surgery and International Study Group of Liver Surgery.
Time frame: Up to 90 days after surgery.
Serum CA 19-9 and CEA response
The change in carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) after surgery and after 4, 8, and 12 cycles of mFOLFIRINOX compared to baseline.
Time frame: 9 months
Clinical response rate according to RECIST criteria version 1.1
Response comparing baseline and restaging after 4 and 8 cycles of mFOLFIRINOX
Time frame: At the time of surgery.
Patient reported cancer-specific health-related Quality of Life (HRQoL) as assessed using the EORTC QLQ-C30
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported non-disease specific HRQoL as assessed using the EQ-5D-5L
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported tumor-specific HRQoL as assessed using the EORTC LQPAN26
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported Quality of Life as assessed using the worry of progression of cancer scale (WOPS)
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported chemotherapy-induced peripheral neuropathy as assessed using the EORTC QLQ-CIPN20
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported Quality of Life as assessed using the happiness, hospital, anxiety and depression scale (HADS)
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire
At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year
Time frame: Up to 5 years after randomization.
Plan to share: Yes
Started Sep 2021 (actual). Primary completion is estimated for Jan 2027, 64 months after the start.
Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 64 months is close to that.
Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Leucovorin · Fluorouracil · Irinotecan · Oxaliplatin